Follow us: facebook twitter linkedin
Login My ASCCP Search

News & Announcements

FDA Approves a New HPV Vaccine

On Wednesday, December 10, 2014, the U.S. Food and Drug Administration (FDA) approved a new 9-valent Human papillomvirus (HPV) vaccine which protects against not only the four types included in the quadrivalent HPV vaccine, available since 2006, but five other types known to cause HPV-associated cancers.  The combination of genotypes in this vaccine will protect against 90% of HPV-associated cancers as well as most external genital warts.  

There are still many questions to be answered about the vaccine’s use, like how many doses will be needed, over what time period will the doses be given, and for whom will it be recommended. Also to be determined is whether or not a recommendation will be made for use of the new vaccine among individuals who’ve already received a full series of the either the quadrivalent or bivalent HPV vaccine.  The CDC Advisory Committee on Immunization Practices is expected to discuss many of these issues at its next meeting, in February, 2015, and proposed recommendations will be voted on at that time.  Until those decisions are made, remember that the quadrivalent HPV vaccine is still available  and is known to be highly effective in preventing external genital warts and HPV-associated cancers.  

ASCCP will be discussing HPV vaccination during its 2015 Clinical Update meeting in Baltimore, MD, June 5-7. Providers, be sure to discuss with your patients whether the vaccine is right for them.  Individuals, be sure to discuss whether the vaccine is right for you or your children with your regular health care provider.


FDA Announcement Expands Options for Cervical Cancer Screening
ASCCP releases statement in response to FDA Announcement

FDA approves first human papillomavirus test for primary cervical cancer screening
Please stay tuned. ASCCP and SGO are in the process of creating a guidance document - available as soon as final ATHENA study data is published.

CETC HPV utilization statement

The Cytopathology Education and Technology Consortium (CETC) recently provided an updated statement on human papillomavirus (HPV) DNA test utilization. This statement is a concise summary of the clinical indications for high-risk or oncogenic HPV testing based on guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). 
--- Erratum

Teresa M. Darragh, MD Receives College of American Pathologists Outstanding Service Award

Congratulations Dr. Darragh, current ASCCP President, for your receipt of the College of American Pathologists Outstanding Service Award. The CAP presents the Outstanding Service Award to its members who provided outstanding service to a single CAP program or project. Dr. Darragh was recognized for her significant contributions as co-chair of The Lower Anogenital Squamous Terminology Standardization Project for Human Papillomavirus (HPV) - associated Lesions or the LAST Project.

The LAST project spanned several years with more than 40 panel members and resulted in a large consensus conference with 35 participating organizations voting on the final recommendations that standardize histopathologic terminology for HPV-associated squamous lesions leading to more reliable and reproducible diagnoses and better patient care.

From Dr. Darragh: 
I am immensely honored to receive the CAP Outstanding Service Award in recognition of the CAP - American Society for Colposcopy and Cervical Pathology (ASCCP) LAST Project. It was a collaborative project whose success is due to the efforts of all involved, particularly to the co-chairs and members of each of the working groups of the LAST Project and the extraordinary staff support from the CAP and the ASCCP.

The ASCCP Guidelines App Gains an Average of 5
​With versions now available for iPad, iPhone, and Android, the ASCCP Guidelines App is receiving rave reviews. Thank you to all who have downloaded the app -- even easier downloading in bulk for your entire staff will be coming soon. If you're using the app, please don't forget to leave a review on iTunes or Google Play. Your reviews help us to spread the word about this great clinical tool to the rest of the industry. Leave your reviews here:  iTunes  and here:  Google Play.

Save The Date -- April 9 - 12, 2014
​The ASCCP Biennial Scientific Meeting is coming to Scottsdale, Arizona. More information on registration and exhibition to come soon.

ASCCP Member News - Congratulations Lisa Ferguson, RN, MSN, WHNP-BC
​ASCCP member Lisa Ferguson, RN, MSN, WHNP-BC, a graduate student in the doctoral program of Texas Woman's University's College of Nursing, will be presented with the prestigious Virginia Chandler Dykes Endowed Scholarship on February 21, 2013.

Press Release
Frederick, MD, March 21, 2013. -- The American Society for Colposcopy and Cervical Pathology (ASCCP) today released the Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

The ASCCP of Service in Rwanda
ASCCP member and International Education & Humanitarian Outreach Committee member Lisa A. Lepine, MD is featured today in the Daily Camera. The article, “Boulder gynecologist passionate about preventive care in developing nations: Treatment and education both part of her medical arsenal,” highlights Dr. Lepine’s and the committee’s trip to the African developing country. More information on the ASCCP's mission will be featured as it becomes available. 

Copyright © 2014. All rights reserved.   Use of this Web site constitutes acceptance of our Terms of Use.